This supplementary appendix provides additional information about the association between SARS-CoV-2 and Guillain-Barré syndrome (GBS). It includes case histories, figures, and tables. Five cases of GBS associated with SARS-CoV-2 are described. Case 1: A 77-year-old woman developed tetraplegia after a fever and respiratory symptoms. She tested positive for SARS-CoV-2 and received IVIg, but her condition worsened. Case 2: A 23-year-old man developed facial palsy and limb weakness after a viral infection. He tested positive for SARS-CoV-2 and received IVIg, which improved his symptoms. Case 3: A 55-year-old man developed tetraparesis after a viral infection. He tested positive for SARS-CoV-2 and received IVIg, but his condition remained critical. Case 4: A 76-year-old man developed tetraparesis after a viral infection. He tested positive for SARS-CoV-2 and received IVIg, which improved his motor function. Case 5: A 61-year-old man developed tetraplegia after a viral infection. He tested negative for SARS-CoV-2, but later tested positive. He received IVIg, but his condition worsened, and he developed pneumonia. Neurophysiological tests showed axonal or demyelinating features in all patients. SARS-CoV-2 IgG was positive in all patients. The appendix also includes a timeline of symptoms and treatments, and tables summarizing neurophysiological and demographic data. The study highlights the association between SARS-CoV-2 and GBS, and the importance of early diagnosis and treatment.This supplementary appendix provides additional information about the association between SARS-CoV-2 and Guillain-Barré syndrome (GBS). It includes case histories, figures, and tables. Five cases of GBS associated with SARS-CoV-2 are described. Case 1: A 77-year-old woman developed tetraplegia after a fever and respiratory symptoms. She tested positive for SARS-CoV-2 and received IVIg, but her condition worsened. Case 2: A 23-year-old man developed facial palsy and limb weakness after a viral infection. He tested positive for SARS-CoV-2 and received IVIg, which improved his symptoms. Case 3: A 55-year-old man developed tetraparesis after a viral infection. He tested positive for SARS-CoV-2 and received IVIg, but his condition remained critical. Case 4: A 76-year-old man developed tetraparesis after a viral infection. He tested positive for SARS-CoV-2 and received IVIg, which improved his motor function. Case 5: A 61-year-old man developed tetraplegia after a viral infection. He tested negative for SARS-CoV-2, but later tested positive. He received IVIg, but his condition worsened, and he developed pneumonia. Neurophysiological tests showed axonal or demyelinating features in all patients. SARS-CoV-2 IgG was positive in all patients. The appendix also includes a timeline of symptoms and treatments, and tables summarizing neurophysiological and demographic data. The study highlights the association between SARS-CoV-2 and GBS, and the importance of early diagnosis and treatment.